Shasun receives MHRA, UK approval for bulk tablets

Chennai, Mar 7 (UNI) Shasun Chemicals and Drugs Ltd today announced that it had received approval from Medicines and Healthcare products Regulatory Agency (MHRA), UK, for its WHO-CGMP formulation facility manufacturing Oral Solid Dosage forms (tablet and capsules) for the bulk tablets packing.

Now Shasun's products from its brand new formulation facility could be sold on commercial basis to UK and European countries, a release here said.

The Pondicherry formulation plant with an annual capacity to produce 3.6 billion tablets was completed in mid-2005.

Commenting on the development, Joint Managing Director Vimal Kumar said ''with this first approval for the formulation plant having been received in record time, the company is closer to commercialising its plan in integrating its support operations in the complete value chain of Pharma business.'' Shasun, the largest manufacturer of Ibuprofen in the world enjoyed 25 per cent market share worldwide and supplied Ibuprofen and its value-added products to major regulated markets.

It was also the largest manufacturer of Nizatidine API (Axid) and one of the largest manufacturers of Ranitidine API (Zantac).

UNI HV ROY 1711